AC Immune SA
Business
AC Immune SA is a clinical-stage biopharmaceutical company advancing Precision Medicine approaches for neurodegenerative diseases. It develops therapeutics and diagnostics, including active immunotherapies, monoclonal antibodies, small-molecule Morphomers, and PET imaging tracers targeting Abeta, Tau, alpha-synuclein, TDP-43 and NLRP3‑ASC. Its operations revolve around two proprietary platforms, SupraAntigen and Morphomer, and a pipeline organized into therapeutic and diagnostic programs with collaboration and licensing arrangements. The company advances clinical development primarily in the U.S. and select European markets while partnering with global pharmaceutical companies and contract manufacturing organizations.
Summary from filing dated 2025-03-13
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-70.45M |
| Total assets | $154.25M |
| Total liabilities | $109.37M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is AC Immune SA's CIK number?
AC Immune SA's SEC CIK number is 0001651625 (1651625). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find AC Immune SA's SEC filings?
All of AC Immune SA's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.